Actinic Keratosis – Pipeline Review, H1 2012

Published : March 2012
No. of Pages : 74

Price:

Actinic Keratosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Actinic Keratosis - Pipeline Review, H1 2012', provides an overview of the Actinic Keratosis therapeutic pipeline. This report provides information on the therapeutic development for Actinic Keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Actinic Keratosis. 'Actinic Keratosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Actinic Keratosis.
- A review of the Actinic Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Actinic Keratosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Actinic Keratosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Actinic Keratosis pipeline depth and focus of Actinic Keratosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Actinic Keratosis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Actinic Keratosis 9
Actinic Keratosis Therapeutics under Development by Companies 11
Actinic Keratosis Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Actinic Keratosis Therapeutics – Products under Development by Companies 18
Actinic Keratosis Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Actinic Keratosis Therapeutics Development 20
Mochida Pharmaceutical Co., Ltd. 20
Meda AB 21
Almirall, S.A. 22
NexMed, Inc. 23
Clinuvel Pharmaceuticals Limited 24
Quest PharmaTech Inc. 25
Provectus Pharmaceuticals, Inc. 26
Digna Biotech, S.L. 27
Telormedix SA 28
ELORAC, Inc. 29
Moberg Derma AB 30
Birken GmbH 31
Actinic Keratosis – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
P144 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PH-10 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Scenesse - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TMX-202 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MTD-39 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Celecoxib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Silicon Phthalocyanine 4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Aminolevulinic Acid - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Eflornithine + Triamcinolone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Perillyl Alcohol - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Sotirimod - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LAS41007 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
E-0611 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Oleogel-S-10 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Fluorouracil - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Limtop - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SL017 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Actinic Keratosis Therapeutics – Drug Profile Updates 61
Actinic Keratosis Therapeutics – Discontinued Products 65
Actinic Keratosis Therapeutics - Dormant Products 66
Actinic Keratosis – Product Development Milestones 67
Featured News & Press Releases 67
Jan 25, 2012: FDA Approves LEO Pharma's Picato Gel For Topical Treatment Of Actinic Keratosis 67
Dec 16, 2011: European Commission Authorizes EU-Wide Marketing And Distribution Of Biofrontera's Ameluz 67
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 68
Oct 21, 2011: Biofrontera Announces EMA Recommends Approval Of BF-200 ALA 68
Sep 22, 2011: Biofrontera Delivers Final Documents For Processing Last Open Issues In Drug Application Of BF-200 ALA 68
Jul 19, 2011: Graceway Receives FDA Approval For Zyclara 69
Jun 06, 2011: LEO Pharma Presents Data From Four Phase III Studies Of Ingenol Mebutate At World Congress Of Dermatology 69
May 31, 2011: Biofrontera Enforces Arrangements For Market Launch Of BF-200 ALA 70
May 12, 2011: Clinuvel Receives EMA Approval For New Drug Filing In Europe In 2011 71
Jan 27, 2011: Biofrontera Receives Positive Review From European Medicines Agency For Approval Process Of BF-200 ALA 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products Under Development for Actinic Keratosis, H1 2012 9
Products under Development for Actinic Keratosis – Comparative Analysis, H1 2012 10
Number of Products under Development by Companies, H1 2012 12
Number of Products under Investigation by Universities/Institutes, H1 2012 13
Comparative Analysis by Late Stage Development, H1 2012 14
Comparative Analysis by Mid Clinical Stage Development, H1 2012 15
Comparative Analysis by Early Clinical Stage Development, H1 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 17
Products under Development by Companies, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
Mochida Pharmaceutical Co., Ltd., H1 2012 20
Meda AB, H1 2012 21
Almirall, S.A., H1 2012 22
NexMed, Inc., H1 2012 23
Clinuvel Pharmaceuticals Limited, H1 2012 24
Quest PharmaTech Inc., H1 2012 25
Provectus Pharmaceuticals, Inc., H1 2012 26
Digna Biotech, S.L., H1 2012 27
Telormedix SA, H1 2012 28
ELORAC, Inc., H1 2012 29
Moberg Derma AB, H1 2012 30
Birken GmbH, H1 2012 31
Assessment by Monotherapy Products, H1 2012 32
Assessment by Combination Products, H1 2012 33
Assessment by Stage and Route of Administration, H1 2012 35
Assessment by Stage and Molecule Type, H1 2012 37
Actinic Keratosis Therapeutics – Drug Profile Updates 61
Actinic Keratosis Therapeutics – Discontinued Products 65
Actinic Keratosis Therapeutics – Dormant Products 66

List of Figures
Number of Products under Development for Actinic Keratosis, H1 2012 9
Products under Development for Actinic Keratosis – Comparative Analysis, H1 2012 10
Products under Development by Companies, H1 2012 11
Products under Investigation by Universities/Institutes, H1 2012 13
Late Stage Products, H1 2012 14
Mid Clinical Stage Products, H1 2012 15
Early Clinical Stage Products, H1 2012 16
Pre-Clinical Stage Products, H1 2012 17
Assessment by Monotherapy Products, H1 2012 32
Assessment by Combination Products, H1 2012 33
Assessment by Route of Administration, H1 2012 34
Assessment by Stage and Route of Administration, H1 2012 35
Assessment by Molecule Type, H1 2012 36
Assessment by Stage and Molecule Type, H1 2012 37

Actinic Keratosis – Pipeline Review, H1 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: